| P2093 | author name string | Jeffrey S Freeman | |
| P2860 | cites work | The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. | Q51376983 |
| | Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. | Q51378688 |
| | Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study | Q83386003 |
| | Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study | Q83489553 |
| | 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial | Q84502143 |
| | Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes | Q86122041 |
| | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| | Standards of medical care in diabetes--2013 | Q29620309 |
| | Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. | Q30588344 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 |
| | Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes | Q42496887 |
| | Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. | Q42837261 |
| | Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes | Q43087481 |
| | Ambulatory medical care utilization estimates for 2007. | Q45293414 |
| | Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes--National Health and Nutrition Examination Survey, United States, 2007-2010. | Q46955100 |
| | Achievement of goals in U.S. diabetes care, 1999-2010. | Q51045064 |
| | Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. | Q51365744 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| | metformin | Q19484 |
| P304 | page(s) | 212256 | |
| P577 | publication date | 2013-08-21 | |
| P1433 | published in | Drugs in context | Q26842115 |
| P1476 | title | Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin | |
| P478 | volume | 2013 | |